ACC Patent Committee Meeting

Sponsored by

Market Exclusivity – FDA Considerations in Patent Product Protection Strategies 



Wednesday, October 9, 2019

4:30 PM - 6:30 PM

Registration: 4:30 p.m. - 5 p.m. 
Program: 5 p.m. – 6 p.m.
Networking: 6 p.m. – 6:30 p.m

Sheppard Mullin Office
Four Embarcadero Center,

Seventeenth Floor
San Francisco, CA 94111


Description: Protecting a company’s substantial investment in drug and biologic discovery is key to a product’s commercial success.  Market exclusivity has the potential to drive innovation for large and small molecules, and also orphan drugs and other niche drugs with a limited market.  In this session, we will explore strategies for maximizing exclusivity from both a patent and FDA regulatory perspective.  We also will discuss the opportunities and challenges of attaining market exclusivity from in-house attorneys at both large and small molecule companies. 


Lorna Tanner: Partner, Sheppard Mullin

Allison Fulton: Partner, Sheppard Mullin

Lauren Stevens: Consultant, Global Patent Group, LLC 

Leslie Robbins:  Senior VP Intellectual Property, CytomX Therapeutics 


    1.0 Hours MCLE Credit


NovemberDecember 2019January
Click a date in the calendar to view its details.